Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Parallel-Group, Single-Dose, Phase 1, Open-Label Study to Investigate the Pharmacokinetics of LY3437943 in Participants With Hepatic Impairment Compared With Healthy Participants

NCT05916560 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT05916560
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05916560 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Parallel-Group, Single-Dose, Phase 1, Open-Label Study to Investigate the Pharmacokinetics of LY3437943 in Participants With Hepatic Impairment Compared With Healthy Participants
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
July 13, 2023
Completion date
March 2, 2025
Enrollment
43 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

healthy, hepatic insufficiency